Document Detail


Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: a single institution's experience.
MedLine Citation:
PMID:  15543011     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The authors reviewed the medical records of 42 children younger than 13 years of age diagnosed with Burkitt lymphoma at the American University of Beirut Medical Center between 1983 and 1993. The male:female ratio was 3.9. The abdomen was the most common site of disease (86%). Jaw, central nervous system, and bone marrow involvement occurred in 16.6%, 16.6%, and 9.5%, respectively. The mean LDH level was 447 U/L. The mean age at diagnosis was 6.9 years. Thirty-nine patients received a variation of the COMP protocol. The total duration of treatment ranged from 6 to 18 months. At a median follow-up of 5 years the event-free survival was 100% for children with stages I and II disease, 77.4% (+/- 2 SE) for stage III, and 0% for stage IV. Failures in stage III patients were due to tumor lysis (3/24) and progressive disease (2/24). Aggressive therapy with high doses of methotrexate and anthracyclines may not be necessary for the treatment of children with extensive abdominal disease (stage III) in Lebanon. If confirmed in a larger series of patients, this study could have a major impact on the treatment of Burkitt lymphoma in Lebanon and other countries with limited resources.
Authors:
Samar A Muwakkit; Bassem I Razzouk; Nina S Shabb; Michael L Hancock; Ibrahim Dabbous; Salim Firzli; Miguel R Abboud
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  26     ISSN:  1077-4114     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-11-15     Completed Date:  2004-12-21     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  749-53     Citation Subset:  IM    
Affiliation:
Children's Cancer Center of Lebanon, American University of Beirut, Lebanon. sm03@aub.edu.lb
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antineoplastic Combined Chemotherapy Protocols* / administration & dosage,  therapeutic use*
Burkitt Lymphoma / complications,  diagnosis*,  drug therapy*
Child
Child, Preschool
Cyclophosphamide / administration & dosage
Disease-Free Survival
Female
Follow-Up Studies
Humans
Infant
Lebanon
Male
Methotrexate / administration & dosage
Neoplasm Staging
Prednisone / administration & dosage
Retrospective Studies
Treatment Failure
Treatment Outcome
Vincristine / administration & dosage
Chemical
Reg. No./Substance:
50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A comprehensive study of the neonatal manifestations of congenital dyserythropoietic anemia type I.
Next Document:  Posttraumatic intracerebral venous thrombosis: an infant who has fallen off a hammock.